Predictive In Vitro Models
Developing Better Models to Predict Clinical Outcomes
21 – 22 September 2011
Double Tree Suites Hilton, Boston, MA, USA
Day Two
Thursday 22nd September, 2011
08:15 Breakfast
09.00 Chair’s Opening Remarks- Donna Dambach, Director, Investigative Toxicology, Genentech
Evaluating The Performance Of In Vitro Models
09.10 Review of the Use and Performance of In Vitro Safety Pharmacology Assays
Confirmed: Laszlo Urban, Global Head, Preclinical Safety Profiling, Novartis
09.45 Evaluating the Potential of New In Vitro Models to Predict Hepatotoxicity Hazard
Confirmed: Michael Aleo, Research Fellow, Pfizer
New Opportunities through the use of Stem Cells in the Drug Development Proces
10.20 Application of Induced Pluripotent Stem (iPS) Cell-Based Models in Drug Development
Chris Parker, Chief Commercial Officer, Cellular Dynamics International
10.55 Morning refreshments
11.25 Development of Stem Cell-Based Safety Assessment Strategies for Screening and Investigation
Confirmed: Hirdesh Uppal, Scientist, Genentech
12.00 Using Stem Cells to Predict Efficacy on a Pre-Clinical Basis
Confirmed: Mark Thiede, Research Fellow, Pfizer
12.35 Lunch
Advances In Predictive Modeling
1.35 Scaffold-Free 3D Multi-cellular Microtissues Provide High Content
Confirmed: Jeffrey Morgan, Associate Professor of Medical Science & Engineering, Co-Director, Center for Biomedical Engineering, Brown University
2.10 Novel Lab-on-a-Chip Platforms for Precise and High- Throughput Cell Analysis
Confirmed: Andre Levchenko, Assistant Professor, The John Hopkins University
2.45 Afternoon refreshments
3.15 Natural Polymeric Biomaterials for Tissue Engineering Applications
Confirmed: Hojae Bae, Instructor, Harvard Medical School
3.50 PANEL DISCUSSION
Developing New Models with Industry in Mind: The Importance of Collaborative Partnerships with Drug Developers, Academia and Platform Providers
Confirmed: Jeffrey Morgan, Associate Professor of Medical Science & Engineering, Co-Director, Center for Biomedical Engineering, Brown University
Confirmed: Laszlo Urban, Global Head, Preclinical Safety Profiling, Novartis
Confirmed: Ernie Bush, Vice President, Collaborative Projects, The Drug Safety Executive Council